| Bioactivity | SARS-CoV-2 Mpro-IN-9 (compound c7) is a nonpeptidic, noncovalent SARS-CoV-2 Mpro inhibitor (IC50=0.085 μM), with improved physicochemical and drug metabolism and pharmacokinetics (DMPK) properties. SARS-CoV-2 Mpro-IN-9 inhibits viral replication (EC50=1.10 μM) in SARS-CoV-2-infected Vero E6 cells, while exhibits low cytotoxic effects (CC50>50 μM)[1]. |
| Target | IC50: 0.085 μM (SARS-CoV-2), EC50: 1.10 μM (viral replication) |
| Name | SARS-CoV-2 Mpro-IN-9 |
| CAS | 2754370-99-3 |
| Formula | C20H14N2O4 |
| Molar Mass | 346.34 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Zhang K, et al. Discovery of quinazolin-4-one-based non-covalent inhibitors targeting the severe acute respiratory syndrome coronavirus 2 main protease (SARS-CoV-2 Mpro). Eur J Med Chem. 2023 Sep 5;257:115487. |
SARS-CoV-2 Mpro-IN-9
CAS: 2754370-99-3 F: C20H14N2O4 W: 346.34
SARS-CoV-2 Mpro-IN-9 (compound c7) is a nonpeptidic, noncovalent SARS-CoV-2 Mpro inhibitor (IC50=0.085 μM), with improv
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.